As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?

Summary: U.S. lawmakers want to stop American drug companies from buying medical research from China. Right now, many U.S. companies save money by using Chinese science to start new drug projects. But politicians want to expand a national security law called the COINS Act to block these deals. They worry that relying on China will hurt American science in the long run. On the other hand, some biotech leaders say blocking these deals will just make medicines more expensive and delay new treatments. They think the U.S. should fix its own rules and funding instead of building a wall against foreign research.

Source: Fierce Biotech URL: fiercebiotech.com/biotech/calls-coins-act-expansion-grow-new-rules-sweep-china-biotech-licensing (opens in new tab)